Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging

Wu, Qiaoyi; Wu, Liang; Wang, Yuzhe; Zhu, Zhi; Song, Yanling; Tan, Yuyu; Wang, Xingfu; Li, Jiuxing; Kang, Dezhi; Yang, Chaoyong

doi:10.1016/j.bios.2016.01.031

Cited by 35 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with other ligands, aptamers have several attractive features, including diverse structure, high specificity, high stability, rapid tissue penetration, no immunogenicity, and easy synthesis and modification. [26][27][28][29] Molecular probes loaded with specific aptamers can specifically gather in target tissues and achieve molecular imaging of target tissues. 15,30 This study prepared targeted lipid nanobubbles loaded with CAIX aptamer, explored their specific binding ability, and targeted imaging ability in various tumors, and further investigated the morphological basis of USMI in vivo.…”

Section: Introductionmentioning

confidence: 99%

CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

Zhu¹,

Wang²,

Liu³

et al. 2018

IJN

View full text Add to dashboard Cite

PurposeTargeted nanobubbles can penetrate the tumor vasculature and achieve ultrasound molecular imaging (USMI) of tumor parenchymal cells. However, most targeted nanobubbles only achieve USMI of tumor parenchymal cells from one organ, and their distribution, loading ability, and binding ability in tumors are not clear. Therefore, targeted nanobubbles loaded with carbonic anhydrase IX (CAIX) aptamer were fabricated for USMI of various tumors, and the morphological basis of USMI with targeted nanobubbles was investigated.Materials and methodsThe specificity of CAIX aptamer at the cellular level was measured by immunofluorescence and flow cytometry. Targeted nanobubbles loaded with CAIX aptamer were prepared by a maleimidethiol coupling reaction, and their binding ability to CAIX-positive tumor cells was analyzed in vitro. USMI of targeted and non-targeted nanobubbles was performed in tumor-bearing nude mice. The distribution, loading ability, and binding ability of targeted nanobubbles in xenograft tumor tissues were demonstrated by immunofluorescence.ResultsCAIX aptamer could specifically bind to CAIX-positive 786-O and Hela cells, rather than CAIX-negative BxPC-3 cells. Targeted nanobubbles loaded with CAIX aptamer had the advantages of small size, uniform distribution, regular shape, and high safety, and they could specifically accumulate around 786-O and Hela cells, while not binding to BxPC-3 cells in vitro. Targeted nanobubbles had significantly higher peak intensity and larger area under the curve than non-targeted nanobubbles in 786-O and Hela xenograft tumor tissues, while there was no significant difference in the imaging effects of targeted and non-targeted nanobubbles in BxPC-3 xenograft tumor tissues. Immunofluorescence demonstrated targeted nanobubbles could still load CAIX aptamer after penetrating the tumor vasculature and specifically binding to CAIX-positive tumor cells in xenograft tumor tissues.ConclusionTargeted nanobubbles loaded with CAIX aptamer have a good imaging effect in USMI of tumor parenchymal cells, and can improve the accuracy of early diagnosis of malignant tumors from various organs.

show abstract

Section: Introductionmentioning

confidence: 99%

CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

Zhu¹,

Wang²,

Liu³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…In addition, among a group of DNA aptamers selected on a cell line (K308) derived from gliosarcoma, a variant of GBM, WQY-9 aptamer was capable of recognizing gliosarcoma cells and gliosarcoma tissues, differentiating gliosarcoma from GBM [93].…”

Section: Gbmmentioning

confidence: 99%

Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof

et al. 2021

View full text Add to dashboard Cite

The identification of tumor cell-specific surface markers is a key step towards personalized cancer medicine, allowing early assessment and accurate diagnosis, and development of efficacious targeted therapies. Despite significant efforts, currently the spectrum of cell membrane targets associated with approved treatments is still limited, causing an inability to treat a large number of cancers. What mainly limits the number of ideal clinical biomarkers is the high complexity and heterogeneity of several human cancers and still-limited methods for molecular profiling of specific cancer types. Thanks to the simplicity, versatility and effectiveness of its application, cell-SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology is a valid complement to the present strategies for biomarkers’ discovery. We and other researchers worldwide are attempting to apply cell-SELEX to the generation of oligonucleotide aptamers as tools for both identifying new cancer biomarkers and targeting them by innovative therapeutic strategies. In this review, we discuss the potential of cell-SELEX for increasing the currently limited repertoire of actionable cancer cell-surface biomarkers and focus on the use of the selected aptamers as components of innovative conjugates and nano-formulations for cancer therapy.

show abstract

“…The absence of specific biomarkers for CSCs impedes the development of effective therapies against them. 43 Cell-SELEX was also performed against cell lines of PDAC, 44 gliosarcoma, 45 and liver, 46,47 colorectal, 48 lung, 30,49 prostate, 50 and breast cancer, 51 among others. With the aim of finding a new biomarker for the diagnosis of PDAC, Dua et al 52 carried out cell-SELEX against two target human pancreatic cell lines, Panc-1 and Capan-1, using normal human pancreatic ductal cells for negative selection.…”

Section: Cell-selex Targeting Unrevealed Receptorsmentioning

confidence: 99%

Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

Sola

Menon

Moreno

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging

Cited by 35 publications

References 52 publications

CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors

Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof

Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

Contact Info

Product

Resources

About